Navigation Links
Study: Child maltreatment victims lose 2 years of quality of life
Date:5/28/2008

ic health officials to compare the costs and benefits of two unrelated public health interventions.

To assess reductions in quality of life, the team matched responses to a survey that assessed physical functioning, pain, cognitive functioning and social support with data from surveys that explicitly asked people how many years of life they would trade to be free of a given health condition. The result is a score that ranges from 0 to 1, with 0 being equivalent to death and 1 being perfect health. The average score for people who werent maltreated was .78, while the score for those were was .75 a difference of .03 per year. Throughout a lifetime, this figure translates to a loss of two years of quality-adjusted life expectancy.

Every year gets diminished in some respect, Corso said, because the person who was maltreated has a lower quality of life than the person who wasnt.

The long-term consequences of child maltreatment are very real and concerning. All children should have safe, stable and nurturing environments in which to grow and develop, said Ileana Arias, director of CDCs National Center for Injury Prevention and Control. For children and adults to live to their full potential, we must support programs that stop child maltreatment before it ever begins and work to help those who have already experienced it.

The researchers also found significant differences among age groups, with the gap between the non-maltreated and maltreated group growing smallerbut never disappearingin older age groups. The exception, Corso noted, was in the 70 and above group, where the difference between the non-maltreated and maltreated group is actually larger than in the previous two age groups (60 to 69 and 50 to 59). The exact reasons for this difference are unclear, but Corso said older people might have more time to reflect on past maltreatment.

She cautions that the two-year reduction in quality of life undoubtedly underestimates t
'/>"/>

Contact: Sam Fahmy
sfahmy@uga.edu
706-542-5361
University of Georgia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. U of M study: Early treatment can reverse heart damage
2. New study: Pine bark reduces perimenopausal symptoms
3. U of M study: Health food supplement may curb addiction of pathological gamblers
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Kaiser Permanente study: Alcohol amount, not type -- wine, beer, liquor -- triggers breast cancer
6. UGA study: Youth exposed to smokeless tobacco ads despite settlement
7. New National Medicaid Study: Minnesota Under Funds Seniors Nursing Home Care $167 Million Annually
8. Study: Modafinil is effective in treating excessive sleepiness
9. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
10. New study: pine bark extract boosts nitric oxide production
11. Study: HPV test beats Pap in detecting cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 1New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 2Testosterone Therapy May Help Men With Heart Failure 55194 1Testosterone Therapy May Help Men With Heart Failure 55194 2Testosterone Therapy May Help Men With Heart Failure 55194 3